Lantheus Medical Imaging
Focus: Lantheus is a public specialty biotech focused on small-molecule radiopharmaceuticals and imaging agents for oncology, cardiovascular, and metabolic disease detection. The company operates across nuclear medicine, PET, and ultrasound contrast modalities with a portfolio of legacy and emerging diagnostic agents.
Profile data last refreshed 1h ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Lantheus Medical Imaging
AI assessmentNot HiringNo open roles listed right now. Follow Lantheus Medical Imaging to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Lantheus Medical Imaging's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
7 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
XENON XE-133
Declining
LOE Approaching
Legacy radiopharmaceutical with imminent loss of exclusivity; core revenue driver at risk.
Help build intelligence for Lantheus Medical Imaging
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.